We are a Swiss technology company targeting 400 million patients worldwide who suffer from visual impairment due to chronic retinal diseases, to help them improve their patient experience while trying to reduce the overall cost of care.
We are succeeding by developing the first fully automated system capable of performing safe injections into the eye worldwide through the use of robotic-assisted technology.
Combined with our digital health capabilities, we will develop more effective, convenient and safer treatments across the continuum of care for these diseases.
Through our innovative approach, and with the patient population expected to grow by 25% over the next decade, we aim to contribute to the long-term sustainability of healthcare systems by optimising treatment capacity, reducing the overall cost of care, and maximising value for eye patients.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information